The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 12, 2010
Filed:
Nov. 12, 2003
Richard M. Ivey, Parkton, MD (US);
Thomas M. Gentle, Jr., Red Lion, PA (US);
Richard L. Moore, Glenville, PA (US);
Michael L. Towns, Timonium, MD (US);
Nicholas Bachur, Jr., Monkton, MD (US);
Robert W. Rosenstein, Ellicott City, MD (US);
Paul E. Goldenbaum, Hampstead, MD (US);
Song Shi, Reisterstown, MD (US);
Donald Copertino, Catonsville, MD (US);
James Garrett, Baltimore, MD (US);
Gregory Tice, Lutherville, MD (US);
Richard M. Ivey, Parkton, MD (US);
Thomas M. Gentle, Jr., Red Lion, PA (US);
Richard L. Moore, Glenville, PA (US);
Michael L. Towns, Timonium, MD (US);
Nicholas Bachur, Jr., Monkton, MD (US);
Robert W. Rosenstein, Ellicott City, MD (US);
Paul E. Goldenbaum, Hampstead, MD (US);
Song Shi, Reisterstown, MD (US);
Donald Copertino, Catonsville, MD (US);
James Garrett, Baltimore, MD (US);
Gregory Tice, Lutherville, MD (US);
Becton, Dickinson and Company, Franklin Lakes, NJ (US);
Abstract
The early prediction or diagnosis of sepsis advantageously allows for clinical intervention before the disease rapidly progresses beyond initial stages to the more severe stages, such as severe sepsis or septic shock, which are associated with high mortality. Early prediction or diagnosis is accomplished using a molecular diagnostics approach, involving comparing an individual's profile of biomarker expression to profiles obtained from one or more control, or reference, populations, which may include a population who develops sepsis. Recognition of features in the individual's biomarker profile that are characteristic of the onset of sepsis allows a clinician to diagnose the onset of sepsis from a bodily fluid isolated at the individual at a single point in time. The necessity of monitoring the patient over a period of time is, therefore, avoided, advantageously allowing clinical intervention before the onset of serious symptoms. Further, because the biomarker expression is assayed for its profile, identification of the particular biomarkers is unnecessary. The comparison of an individual's biomarker profile to biomarker profiles of appropriate reference populations likewise can be used to diagnose SIRS in the individual.